A Study of ERAS-601 in People With Chordoma

Inclusion Criteria: * Age ≥ 18 years. * Have histologically confirmed chordoma that is not dedifferentiated or poorly differentiated subtype. * Have progressive disease per RECIST 1.1 defined by +20% change between any two scans in the 9 months prior to enrollment. * Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 * Recovered from acute, clinically significant toxicities associated with current/recent treatments to acceptable baseline status * Screening laboratory values must meet the following criteria and should be obtained within 30 days prior to study treatment: * Absolute neutrophil count (ANC) ≥ 1.5 x 103/m * Platelet count ≥ 75 × 103/mL without symptomatic bleeding * Hemoglobin \> 9 g/dL * Serum electrolytes (sodium, potassium, magnesium, phosphorus, calcium) Grade ≤1 or within the institutional ranges of normal. If clinically appropriate, electrolytes may be corrected, and values reassessed prior to enrollment. * AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases * Total bilirubin ≤ 1.5 × ULN (except in patients with Gilbert Syndrome who can have total bilirubin \< 3.0 mg/dL) * Serum creatinine clearance \<1.5 times ULN or ≥ 50 mL/min as determined by Cockcroft-Gault (Appendix 7) (creatinine clearance need not be calculated if serum creatinine is within normal limits). Female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within 7 days p…